2025 年上半年,全球医药监管领域动态频出,众多药企的产品在审批进程中取得关键进展。这些监管决策不仅关乎药企的发展,也为患者带来了新的希望,同时推动着全球医药市场格局的重塑。肿瘤药物:多款新药获批,治疗格局改写肿瘤治疗领域一直是医药创新的前沿阵地,2025 年也不例外。阿斯利康和第一三共的 Enhertu 在欧洲获批用于治疗 HR 阳性、HER2 低表达或超低表达的乳腺癌患者,成为这一特定患者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.